Details of the Drug Combination

General Information of Drug Combination (ID: DC4IFTT)

Drug Combination Name
Ginsenoside Rb1 Cerivastatin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Ginsenoside Rb1   DMF70AB Cerivastatin   DMXCM7H
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.48
Bliss Independence Score: 3.48
Loewe Additivity Score: 3.98
LHighest Single Agent (HSA) Score: 4.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Ginsenoside Rb1 Interacts with 23 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-glucosidase (bglA) DEUO7V8 A0A509DD13_9STRE Metabolism [4]
Beta-glucosidase (bglA) DE4LKZ9 A0A3D1ZWL4_9BIFI Metabolism [4]
Beta-glucosidase (bglA) DEM6GYO A0A351PC96_9FIRM Metabolism [5], [4]
Beta-glucosidase (bglA) DE9N4OU C6WCL5_ACTMD Metabolism [6]
Beta-glucosidase (bglA) DERPJZ6 A0A4Q4LS82_BIFAN Metabolism [7]
Beta-glucosidase (bglA) DEVLXCG R7LVY8_9FUSO Metabolism [4]
Beta-glucosidase (bglA) DEUQTKA A0A249DCH3_LACRH Metabolism [7]
Beta-glucosidase (bglA) DEXRUS1 A0A267WL33_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DERX7ML A0A3B8TKP6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEOHI3U A0A0P0FEZ9_BACT4 Metabolism [8]
Beta-glucosidase (bglA) DE46IH1 A0A1T4QCU7_9PROT Metabolism [9]
Beta-glucosidase (bglA) DEE8WXK A0A076JJU4_BIFAD Metabolism [8]
Beta-glucosidase (bglA) DECBSVP A0A126SWK8_9BIFI Metabolism [8]
Beta-glucosidase (bglA) DEAVLU4 BGLFU_BIFBR Metabolism [8]
Beta-glucosidase (bglA) DEPBQES BGLS_BUTFI Metabolism [8]
Beta-glucosidase (bglA) DEGVUWH A0A174JG46_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE8RS0 A0A174GPV4_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEC0M8H A0A174ZK85_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DE2OMS0 A0A173UNF6_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEPUNVR A0A395V8H8_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEX7SAW A0A3R6A2W5_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEE3I1P A0A412BAD0_9FIRM Metabolism [8]
Beta-glucosidase (bglA) DEASJG5 A5ZMW4_9FIRM Metabolism [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DME(s)
Ginsenoside Rb1 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
Indication(s) of Cerivastatin
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Approved [2]
Multiple myeloma 2A83 Phase 1/2 [3]
Cerivastatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Cerivastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
Sodium/taurocholate cotransporting polypeptide (SLC10A1) DT56EKP NTCP_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [13]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Cerivastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [16]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [18]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [18]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [19]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Cerivastatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Increases ADR [20]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2950).
3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4 Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
5 Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol. 1998 Oct;50(10):1155-60.
6 Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
7 Fermentation of protopanaxadiol type ginsenosides (PD) with probiotic Bifidobacterium lactis and Lactobacillus rhamnosus. Appl Microbiol Biotechnol. 2017 Jul;101(13):5427-5437.
8 Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
9 Genus Enhydrobacter Staley et al. 1987 should be recognized as a member of the family Rhodospirillaceae within the class Alphaproteobacteria. Microbiol Immunol. 2012 Jan;56(1):21-6.
10 Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. Reprod Sci. 2014 Oct;21(10):1312-8. doi: 10.1177/1933719114525269. Epub 2014 Mar 10.
11 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13 FDA Drug Development and Drug Interactions
14 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
15 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
18 Drug Interactions Flockhart Table
19 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
20 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.